Immunogen (IMGN) – Hot Corp. News
-
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $31.26 Per Share, $10.1 Billion
-
Immunogen (IMGN) Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer Doesn't Meet Primary Endpoint
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to IMGN Stock Lookup